Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana?
D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016700:Encainide; D005424:Flecainide / Q000627:therapeutic use; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D016677:Tocainide
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D016677:Tocainide; D008012:Lidocaine; D005424:Flecainide; D000638:Amiodarone; D016700:Encainide